title: Comparison of accelerated partial breast irradiation via multicatheter interstitial brachytherapy versus whole breast radiation.
abstract: BACKGROUND
  Brachytherapy as adjuvant treatment for early-stage breast cancer has become widely available and offers patients an expedited treatment schedule. Given this, many women are electing to undergo brachytherapy in lieu of standard fractionation radiotherapy. We compare outcomes between patients treated with accelerated partial breast irradiation (APBI) via multicatheter interstitial brachytherapy versus patients who were also eligible for and offered APBI but who chose whole breast radiation (WBI).
  
  
  METHODS
  Patients treated from December 2002 through May 2007 were reviewed. Selection criteria included patients with pTis-T2N0 disease, ≤ 3 cm unifocal tumors, and negative margins who underwent breast conservation surgery. Local control (LC), cause-specific (CSS) and overall survival (OS) were analyzed.
  
  
  RESULTS
  202 patients were identified in the APBI cohort and 94 patients in the WBI cohort. Median follow-up for both groups exceeded 60 months. LC was 97.0% for the APBI cohort and 96.2% for the WBI cohort at 5 years (ns). Classification by 2010 ASTRO APBI consensus statement categories did not predict worse outcomes.
  
  
  CONCLUSIONS
  APBI via multicatheter interstitial brachytherapy provides similar local failure rates compared to WBI at 5 years for properly selected patients. Excellent results were seen despite the high fraction of younger patients (< 60 years old) and patients with DCIS.
authors.affiliation: Department of Radiation Oncology and Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO 63110, USA.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Ferraro
authors.forename: Adam A
authors.initials: AA
authors.lastname: Garsa
authors.forename: Todd A
authors.initials: TA
authors.lastname: DeWees
authors.forename: Julie A
authors.initials: JA
authors.lastname: Margenthaler
authors.forename: Michael
authors.initials: M
authors.lastname: Naughton
authors.forename: Rebecca
authors.initials: R
authors.lastname: Aft
authors.forename: William E
authors.initials: WE
authors.lastname: Gillanders
authors.forename: Timothy
authors.initials: T
authors.lastname: Eberlein
authors.forename: Melissa A
authors.initials: MA
authors.lastname: Matesa
authors.forename: Imran
authors.initials: I
authors.lastname: Zoberi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001918:Brachytherapy / Q000295:instrumentation / Q000379:methods*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D057785:Catheters; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D015412:Mastectomy, Segmental; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D018714:Radiotherapy, Adjuvant / Q000295:instrumentation / Q000379:methods*; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents